Načítá se...

Combining immunotherapies for the treatment of prostate cancer

Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate can...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Urol Oncol
Hlavní autoři: Redman, Jason M., Gulley, James L., Madan, Ravi A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6599516/
https://ncbi.nlm.nih.gov/pubmed/29146441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2017.09.024
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!